Strategic Performance Drivers
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Performance was characterized by a strategic shift toward the ADHD market, with Jornay PM revenue growing 41% year-over-year due to record prescriber levels and increased market share.
The acquisition of Azstarys in the second quarter of 2026 serves as a critical lifecycle extension tool, providing IP protection through 2037 and immediate accretion to adjusted EBITDA.
Management views Jornay PM and Azstarys as highly complementary rather than competitive, targeting distinct patient needs for immediate morning control versus rapid-onset flexibility.
Pain portfolio performance was mixed; Belbuca revenue grew 10% on stable demand, but total pain revenue was weighed down by significant pricing pressure on NUCYNTA authorized generics.
Operational efficiency improved through the integration of Azstarys, leveraging existing commercial infrastructure with only a modest increase in sales force headcount from 180 to 190 reps.
Strategic positioning is evolving toward a broader CNS and psychiatry focus, utilizing the ADHD ‘beachhead’ to diversify away from the legacy responsible pain management business.
Outlook and Strategic Priorities
Full-year 2026 revenue guidance for Azstarys was increased to $65 million to $75 million based on encouraging early performance and successful sales force training.
Total product revenue guidance was adjusted downward to $825 million to $855 million to account for lower net pricing realizations in the NUCYNTA franchise.
Management expects a significant growth catalyst in the second half of 2026 driven by the back-to-school season, which historically accelerates ADHD prescription volume.
Belbuca is expected to see a volume boost in the fourth quarter following the securing of new formulary access for an additional 9 million lives.
Capital deployment will remain focused on a balanced approach of debt reduction, opportunistic share repurchases, and M&A targeting assets with $300 million to $500 million peak sales potential.
Risk Factors and Structural Changes
NUCYNTA franchise revenue declined 24% year-over-year, primarily driven by lower-than-anticipated net pricing for authorized generic versions.
The company incurred $24.1 million in one-time acquisition-related expenses during the quarter associated with the Azstarys transaction.
Management flagged a potential generic entry for Belbuca by Teva in January 2027, though they maintain an authorized generic agreement as a defensive contingency.
A corporate headquarters relocation to downtown Boston is planned for Q1 2027 to better integrate with the regional life sciences ecosystem.
